Seelos Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Seelos Therapeutics

02/08/2023 03:07

* Seelos Therapeutics Inc  SEEL.OQ   SEEL.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 3 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Seelos Therapeutics
Inc
is for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 3.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Seelos
Therapeutics Inc is $3.5​, above​ its last closing price
of $1.58. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.11       -0.11      -0.12     Missed  -9.1
 Dec. 31 2023  -0.16       -0.13      -0.17     Missed  -30.8
 Sep. 30 2022  -0.08       -0.10      -0.18     Missed  -71.4​
 Jun. 30 2022  -0.15       -0.14      -0.20     Missed  -39.5
 ​​Mar.        -0.18       -0.18      -0.13     Beat    27.8
 31 2022                                                
 Dec. 31 2021  -0.12       -0.11      -0.28     Missed  -154.5
                                                        ​
 Sep. 30 2021  -0.08       -0.08      -0.11     Missed  -29.4
 Jun. 30 2021  -0.14       -0.12      -0.08     Beat    35.5
 This summary was machine generated August 2 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated